Skip to main content
. 2006 Oct;80(19):9779–9788. doi: 10.1128/JVI.00794-06

TABLE 1.

Demographic profile and treatment of study population

Participant Treatment Immunogena No. of vaccinations prior to infection date Interval between last treatment and HIV acquisition (days)b Gender Race Agec (yr) Risk factord
014A-003 Placebo ALVAC/saline 4 67 Male Other 30 MSM
014A-006 Placebo ALVAC/saline 3e 34 Male White 25 MSM
402FIE Placebo ALVAC/saline 4 255 Male White 31 MSM
014A-001 Vaccine vCP205/gp120 4 376 Female Other 33 Low risk
014A-004 Vaccine vCP205 4 242 Male White 35 MSM
014A-005 Vaccine vCP205/gp120 4 392 Male White 43 MSM
014A-008 Vaccine vCP205 4 105 Male Other 41 IDU
014A-009 Vaccine vCP205 4 530 Male White 25 MSM
014A-011 Vaccine vCP205 3e 13 Male White 42 MSM
40287N Vaccine vCP125/gp120 4 1,176 Female Black 22 Low risk
402I03 Vaccine vCP65/gp120 4 577 Male White 32 MSM
402I15 Vaccine vCP205/gp120 5 273 Male White 34 MSM
403-006 Vaccine vCP205/gp160 4 1,589 Male White 38 MSM
2x0226 Vaccine vCP205/gp120 4 215 Male Other 31 MSM
203-033 Vaccine vCP1452 4 157 Male White 27 MSM
203-157 Vaccine vCP1452/gp120 1e 14 Male Black 27 Bisexual
a

Recombinant canarypox vectors are as follows: vCP125 expresses HIV-1 MN gp160 (Pasteur Merieux/Connaught); vCP65 expresses rabies virus glycoprotein (Pasteur Merieux/Connaught); vCP205 expresses HIV-1 envelope gp120 (strain MN) linked to the transmembrane portion of HIV-1 gp41 (strain LAI) and the HIV-1 LAI genes encoding the entire Gag protein and a portion of the Pol sequence, sufficient to evoke the protease portion (Pasteur Merieux/Connaught); vCP1452 expresses HIV-1 envelope gp120 (strain MN) linked to the transmembrane portion of HIV-1 gp41 (strain LAI), the HIV-1 LAI gene encoding the entire Gag protein, a portion of the pol gene encoding the protease, and a synthetic polynucleotide encompassing several known human CTL epitopes from the nef and pol gene products. It also contains sequences encoding the E3L and K3L vaccinia virus proteins into the C6 site (vCP1452) (Virogenetics Corp., Troy, NY, and Sanofi Pasteur, S.A., Marcy L'Etoile, France).

b

See Materials and Methods for the algorithm used for estimating time of HIV-1 infection.

c

Age at enrollment of parent vaccine protocol.

d

MSM, men having sex with men; IDU, injection drug user. All volunteers reported HIV high-risk behavior prior to enrollment, except for those designated.

e

Participant did not complete vaccination regimen.